SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics

SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics These tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures in patients 12 years of age and older.

No comments:

Post a Comment